Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emil Ygland

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
NPJ Parkinson'S Disease|August 3, 2021
Clinical classification systems and long-term outcome in mid- and late-stage Parkinson's diseaseEmil Ygland Rödström, Andreas Puschmann
Brain : a Journal of Neurology|June 28, 2018
Will FTLD-tau work for all when FTDP-17 retires?Emil Ygland, Maria Landqvist Waldö, Elisabet Englund, et al.
Journal of Parkinson'S Disease|November 22, 2021
Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical SubtypesEmil Ygland Rödström, Niklas Mattsson-Carlgren, Shorena Janelidze, et al.
Scandinavian Journal of Gastroenterology|November 5, 2011
Single-institution experience with solid pseudopapillary neoplasm of the pancreasDaniel Ansari, Jacob Elebro, Bobby Tingstedt, et al.
Parkinsonism & Related Disorders|May 13, 2014
Atypical Friedreich ataxia in patients with FXN p.R165P point mutation or comorbid hemochromatosisEmil Ygland, Franco Taroni, Cinzia Gellera, et al.
Alzheimer'S Research & Therapy|January 27, 2018
Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic reviewEmil Ygland, Danielle van Westen, Elisabet Englund, et al.
Parkinsonism & Related Disorders|October 23, 2018
Oral therapy for riboflavin transporter deficiency - What is the regimen of choice?Sorina Gorcenco, Frédéric M Vaz, Anna Tracewska-Siemiatkowska, et al.
Neurobiology of Aging|June 4, 2016
Strong association between glucocerebrosidase mutations and Parkinson's disease in SwedenCaroline Ran, Lovisa Brodin, Lars Forsgren, et al.
Parkinsonism & Related Disorders|August 19, 2019
Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter studyAndreas Puschmann, Itzia Jiménez-Ferrer, Elin Lundblad-Andersson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 10, 2022
The Interaction between HLA-DRB1 and Smoking in Parkinson's Disease RevisitedCloé Domenighetti, Venceslas Douillard, Pierre-Emmanuel Sugier, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
NPJ Parkinson'S Disease|August 3, 2021
Clinical classification systems and long-term outcome in mid- and late-stage Parkinson's diseaseEmil Ygland Rödström, Andreas Puschmann
Brain : a Journal of Neurology|June 28, 2018
Will FTLD-tau work for all when FTDP-17 retires?Emil Ygland, Maria Landqvist Waldö, Elisabet Englund, et al.
Journal of Parkinson'S Disease|November 22, 2021
Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical SubtypesEmil Ygland Rödström, Niklas Mattsson-Carlgren, Shorena Janelidze, et al.
Scandinavian Journal of Gastroenterology|November 5, 2011
Single-institution experience with solid pseudopapillary neoplasm of the pancreasDaniel Ansari, Jacob Elebro, Bobby Tingstedt, et al.
Parkinsonism & Related Disorders|May 13, 2014
Atypical Friedreich ataxia in patients with FXN p.R165P point mutation or comorbid hemochromatosisEmil Ygland, Franco Taroni, Cinzia Gellera, et al.
Alzheimer'S Research & Therapy|January 27, 2018
Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic reviewEmil Ygland, Danielle van Westen, Elisabet Englund, et al.
Parkinsonism & Related Disorders|October 23, 2018
Oral therapy for riboflavin transporter deficiency - What is the regimen of choice?Sorina Gorcenco, Frédéric M Vaz, Anna Tracewska-Siemiatkowska, et al.
Neurobiology of Aging|June 4, 2016
Strong association between glucocerebrosidase mutations and Parkinson's disease in SwedenCaroline Ran, Lovisa Brodin, Lars Forsgren, et al.
Parkinsonism & Related Disorders|August 19, 2019
Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter studyAndreas Puschmann, Itzia Jiménez-Ferrer, Elin Lundblad-Andersson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 10, 2022
The Interaction between HLA-DRB1 and Smoking in Parkinson's Disease RevisitedCloé Domenighetti, Venceslas Douillard, Pierre-Emmanuel Sugier, et al.
Pageof 2